Dermatomyositis is a rare inflammatory disease ... Hence, Dr Himanshi Chaudhary insisted that early diagnosis and treatment are crucial in managing JDM and preventing complications such as ...

Patients often get better with treatment. But while taking these medications, it's important to be careful to avoid getting ...

Cartesian Therapeutics said it has received rare pediatric disease designation from the U.S. Food and Drug Administration for its Descartes-08 treatment of juvenile dermatomyositis.

Descartes-08, Cartesian’s lead mRNA cell therapy candidate, is an autologous mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T) product candidate targeting B-cell maturation antigen ...

US FDA grants rare paediatric disease designation to Cartesian Therapeutics’ Descartes-08 to treat juvenile dermatomyositis: Gaithersburg, Maryland Tuesday, September 10, 2024, ...

VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an ...

Brepocitinib tosylate is a small molecule commercialized by Roivant Sciences, with a leading Phase III program in Dermatomyositis.

has granted Rare Pediatric Disease Designation to Descartes-08 for the treatment of juvenile dermatomyositis (JDM). Descartes-08, Cartesian’s lead mRNA cell therapy candidate, is an autologous ...

a potent small molecule inhibitor of TYK2 and JAK1 for the treatment of dermatomyositis and non-infectious uveitis, in addition to other clinical stage molecules. We advance our pipeline by ...